Clinical Updates From San Antonio




This activity is provided by Integrity Continuing Education, Inc.


This program has been supported by an independent educational grant from Gilead Sciences, Inc.
This activity is supported by an educational grant from Lilly.


Medical conferences are a leading venue for the presentation of practice-changing data in the field of oncology. The San Antonio Breast Cancer Symposium features hundreds of abstracts each year, making it challenging for clinicians to review and assess the vast amount of data. This program breaks down select abstracts by breast cancer type, focusing on truly impactful results that can be put to immediate use in the clinic.

Program Chairs Drs. Rohit and Rahul Gosain are practicing community oncologists and will ask expert faculty Dr. Sara Tolaney, Dr. Stephanie L. Graff, Dr. Erika P. Hamilton, and Dr. Maryam Lustberg the questions that you would ask about the following topics:

  • CDK4/6 inhibitors in HR+/HER2- breast cancer
  • HER2- advanced breast cancer in heavily pretreated patients
  • HER2+ and HER2-low breast cancer
  • Triple-negative breast cancer and neoadjuvant and adjuvant immunotherapies

Rahul Gosain, MD
Medical Director, Wilmot Cancer Institute at Webster
Director, Wilmot Cancer Institute Regional Infusion Services
Assistant Professor of Clinical Medicine
Division of Hematology and Oncology
University of Rochester
Webster, New York

Rohit Gosain, MD
Chair, Department of Hematology and Oncology
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Stephanie L. Graff, MD, FACP
Director of Breast Oncology
Lifespan Cancer Institute
Assistant Professor of Medicine
Brown University
Providence, Rhode Island

Erika P. Hamilton, MD
Director, Breast Cancer & Gynecologic Cancer Research Program
Sarah Cannon Research Institute
Partner, Tennessee Oncology, PLLC
Nashville, Tennessee

Maryam Lustberg, MD, MPH
Director, Breast Program
Department of Breast Medical Oncology
Yale Cancer Center
Yale University
New Haven, Connecticut

Sara Tolaney, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Chief, Division of Breast Oncology
Senior Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Release date: December 23, 2022
Expiration date: December 23, 2023
Estimated time to complete activity: 60 minutes

This educational activity has been designed to meet the needs of medical oncologists and other healthcare providers who treat patients with breast cancer.


Upon completion of this educational activity, participants should be able to:

  • Compare and contrast new and emerging therapies with established treatment options for patients with breast cancer

There are no fees for participating and receiving CME credit for this activity. During the period of December 23, 2022 through December 23, 2023 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Rahul Gosain, MD
Advisory board: AstraZeneca

Rohit Gosain, MD has no real or apparent conflicts of interest to disclose.

Stephanie L. Graff, MD, FACP
Advisory Boards: Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Novartis, Pfizer, SeaGen
Consultant: Gilead Sciences, Pfizer

Erika P. Hamilton, MD
Consultant/Advisory Role: Arcus, Arvinas, AstraZeneca, Daiichi Sankyo, Deciphera Pharmaceuticals, Ellipses Pharma, Greenwich LifeSciences, iTeos, Janssen, Lilly, Loxo, Mersana, Novartis, Orum Therapeutics, Pfizer, Relay Therapeutics, Roche/Genentech, SeaGen, Verascity Science
Research Funding: AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO, Australia, Amgen, Aravive, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Cullinan-Florentine, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InvestisBio, Jacobio, Karyopharm, K-Group Beta, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Vincerx Pharma, Zenith Epigenetics, Zymeworks

Maryam Lustberg, MD, MPH
Consultant: AstraZeneca, Biothermostics, Novartis, Pfizer, pledPharma, Sanofi Aventis

Sara Tolaney, MD, MPH has no real or apparent conflicts of interest to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest